WO2014209389A1 - Maintien de l'inhibition des plaquettes pendant un traitement antiplaquettaire - Google Patents

Maintien de l'inhibition des plaquettes pendant un traitement antiplaquettaire Download PDF

Info

Publication number
WO2014209389A1
WO2014209389A1 PCT/US2013/048735 US2013048735W WO2014209389A1 WO 2014209389 A1 WO2014209389 A1 WO 2014209389A1 US 2013048735 W US2013048735 W US 2013048735W WO 2014209389 A1 WO2014209389 A1 WO 2014209389A1
Authority
WO
WIPO (PCT)
Prior art keywords
cangrelor
p2yi
inhibitor
administration
acting
Prior art date
Application number
PCT/US2013/048735
Other languages
English (en)
Inventor
Lisa Ruderman Chen
Simona SKERJANCE
Jayne Prats
Dawn Bell
Meredith Todd
Original Assignee
The Medicines Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medicines Company filed Critical The Medicines Company
Priority to PCT/US2013/048735 priority Critical patent/WO2014209389A1/fr
Publication of WO2014209389A1 publication Critical patent/WO2014209389A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de réduction ou de maintien de l'inhibition des plaquettes chez un patient par administration de cangrélor avant une intervention chirurgicale invasive. La méthode de la présente invention peut être utilisée pour des patients ayant besoin d'un traitement antiplaquettaire ou présentant un risque de thrombose. La méthode peut en outre être utilisée chez des patients qui ont été traités précédemment par des inhibiteurs de plaquettes à action prolongée sans augmenter le risque de saignement excessif.
PCT/US2013/048735 2013-06-26 2013-06-26 Maintien de l'inhibition des plaquettes pendant un traitement antiplaquettaire WO2014209389A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2013/048735 WO2014209389A1 (fr) 2013-06-26 2013-06-26 Maintien de l'inhibition des plaquettes pendant un traitement antiplaquettaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/048735 WO2014209389A1 (fr) 2013-06-26 2013-06-26 Maintien de l'inhibition des plaquettes pendant un traitement antiplaquettaire

Publications (1)

Publication Number Publication Date
WO2014209389A1 true WO2014209389A1 (fr) 2014-12-31

Family

ID=52142510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/048735 WO2014209389A1 (fr) 2013-06-26 2013-06-26 Maintien de l'inhibition des plaquettes pendant un traitement antiplaquettaire

Country Status (1)

Country Link
WO (1) WO2014209389A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622893B2 (en) 2020-04-09 2023-04-11 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
WO2023067625A1 (fr) * 2021-10-19 2023-04-27 Sastra Deemed University Composé antifongique, composition et leurs utilisations
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110112030A1 (en) * 2009-11-11 2011-05-12 The Medicines Company Methods of treating or preventing stent thrombosis
WO2011134478A2 (fr) * 2010-04-29 2011-11-03 Thrombologic Aps Méthodes de traitement de patients présentant un risque accru de développer des événements ischémiques et composés associés
US20110288043A1 (en) * 2008-05-13 2011-11-24 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288043A1 (en) * 2008-05-13 2011-11-24 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20110112030A1 (en) * 2009-11-11 2011-05-12 The Medicines Company Methods of treating or preventing stent thrombosis
WO2011134478A2 (fr) * 2010-04-29 2011-11-03 Thrombologic Aps Méthodes de traitement de patients présentant un risque accru de développer des événements ischémiques et composés associés

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANGIOLILLO ET AL.: "Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study", CIRCULATION, vol. 115, 29 January 2007 (2007-01-29), pages 708 - 716 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622893B2 (en) 2020-04-09 2023-04-11 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
US11654057B2 (en) 2020-04-09 2023-05-23 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
WO2023067625A1 (fr) * 2021-10-19 2023-04-27 Sastra Deemed University Composé antifongique, composition et leurs utilisations
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
US10022391B2 (en) Maintenance of platelet inhibition during antiplatelet therapy
US11510934B2 (en) Maintenance of platelet inhibition during antiplatelet therapy
US9320754B2 (en) Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) Maintenance of platelet inhibition during antiplatelet therapy
WO2014163656A1 (fr) Maintien de l'inhibition des plaquettes pendant une thérapie antiplaquettaire
US20230210880A1 (en) Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events
WO2014209389A1 (fr) Maintien de l'inhibition des plaquettes pendant un traitement antiplaquettaire
JP6840197B2 (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
BR112012011298B1 (pt) Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13888276

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13888276

Country of ref document: EP

Kind code of ref document: A1